Evidence map›Paper›PMID 22509362›Full record

ArticlePloS one2012

Deregulation of CREB signaling pathway induced by chronic hyperglycemia downregulates NeuroD transcription.

In-Su Cho, Miyoung Jung, Ki-Sun Kwon, Eunpyo Moon, Jang-Hyeon Cho, Kun-Ho Yoon, Ji-Won Kim, Young-Don Lee, Sung-Soo Kim, Haeyoung Suh-Kim

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
3.2field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 24 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

In-Su ChoDepartment of Anatomy, Ajou University, Suwon, South Korea.
Miyoung Jung
Ki-Sun Kwon
Eunpyo Moon
Jang-Hyeon Cho
Kun-Ho Yoon
Ji-Won Kim
Young-Don Lee
Sung-Soo Kim
Haeyoung Suh-Kim
Ajou University · KRCatholic University of Korea · KRBaylor College of Medicine · USKorea Research Institute of Bioscience and Biotechnology · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

CREB mediates the transcriptional effects of glucose and incretin hormones in insulin-target cells and insulin-producing β-cells. Although the inhibition of CREB activity is known to decrease the β-cell mass, it is still unknown what factors inversely alter the CREB signaling pathway in β-cells. Here, we show that β-cell dysfunctions occurring in chronic hyperglycemia are not caused by simple inhibition of CREB activity but rather by the persistent activation of CREB due to decreases in protein phophatase PP2A. When freshly isolated rat pancreatic islets were chronically exposed to 25 mM (high) glucose, the PP2A activity was reduced with a concomitant increase in active pCREB. Brief challenges with 15 mM glucose or 30 µM forskolin after 2 hour fasting further increased the level of pCREB and consequently induced the persistent expression of ICER. The excessively produced ICER was sufficient to repress the transcription of NeuroD, insulin, and SUR1 genes. In contrast, when islets were grown in 5 mM (low) glucose, CREB was transiently activated in response to glucose or forskolin stimuli. Thus, ICER expression was transient and insufficient to repress those target genes. Importantly, overexpression of PP2A reversed the adverse effects of chronic hyperglycemia and successfully restored the transient activation of CREB and ICER. Conversely, depletion of PP2A with siRNA was sufficient to disrupt the negative feedback regulation of CREB and induce hyperglycemic phenotypes even under low glucose conditions. Our findings suggest that the failure of the negative feedback regulation of CREB is the primary cause for β-cell dysfunctions under conditions of pathogenic hyperglycemia, and PP2A can be a novel target for future therapies aiming to protect β-cells mass in the late transitional phase of non-insulin dependent type 2 diabetes (NIDDM).

Indexed as

AnimalsBasic Helix-Loop-Helix ProteinsCells, CulturedCricetinaeCyclic AMP Response Element-Binding ProteinDiabetes Mellitus, Type 2Gene Expression RegulationGlucoseHumansHyperglycemiaInsulinInsulin-Secreting CellsInsulin SecretionProtein Phosphatase 2RatsRats, Sprague-DawleyBasic Helix-Loop-Helix ProteinsCyclic AMP Response Element-Binding ProteinGlucoseInsulinNeurod1 protein, ratProtein Phosphatase 2RNA, Small Interfering

Identifiers

PMID22509362
PMCPMC3318007
OpenAlexW1985882147

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.